Expert Insight: Developing an assay platform for screening and characterization of antibody-drug conjugates

Don't miss this webinar to find out how researchers at LifeArc are using ALK-specific antibodies as a mechanism of directly targeting ALK-expressing neuroblastoma cells

27 Feb 2020



Dr. Rachel Forfar, Senior Scientist, Asset Delivery, LifeArc

Oncogenic mutations of anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase, have been identified in a number of carcinomas. More recently, overexpression of mutated ALK has been linked to neuroblastoma cancer cells and is associated with poor prognosis in young patients. While current therapies target intracellular signaling cascades, ALK mutant variants demonstrate kinase inhibitor resistance, and therefore new mechanisms to target these cancer cells are crucial for better treatment.

Join this webinar to discover how researchers at LifeArc are investigating a novel approach whereby cytotoxic agents are conjugated to ALK-specific antibodies as a mechanism of directly targeting ALK-expressing neuroblastoma cells.

 

 

Join this webinar to get an overview of:

  • LifeArc cell-based assays that utilize advanced flow cytometry and live-cell analysis
  • An assessment of cell cytotoxicity using secondary antibodies conjugated to potent toxins
  • The challenges of screening, from initial stages with hybridoma supernatants, through to candidate antibodies and towards effectively identifying antibodies with the desired properties of an antibody-drug conjugate (ADC)

Attend the live webinar on Tuesday, March 17, at:

  • 16:00 GMT 
  • 12:00 EDT 
  • 09:00 PDT 
  • 17:00 CET

SelectScience runs 3-4 webinars a month across various scientific topics, discover more of our upcoming webinars>>